Emerging evidence of the impact of kidney disease on drug metabolism and transport.
about
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal diseaseRenal insufficiency and cancer treatmentsA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDEffects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritisWhat Do We Know about Opioids and the Kidney?A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsPharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrationsEffects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolitesPharmacokinetics of mycophenolic acid in patients with lupus nephritis.Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I studyPopulation pharmacokinetic meta-analysis of vortioxetine in healthy individualsEffect of renal or hepatic impairment on the pharmacokinetics of mirabegron.Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver.Indoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3.Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenThe Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativenessHepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobioticsUse of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseasesInfluence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomersPhase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.ESRD impairs nonrenal clearance of fexofenadine but not midazolam.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisHemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.Role of membrane transporters in the safety profile of drugs.In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases.Cockcroft-Gault revisited: New de-liver-ance on recommendations for use in cirrhosisXenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolismClinical Pharmacokinetics and Pharmacodynamics of Afatinib.Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.
P2860
Q24613855-DD7C194F-CB47-48E4-8BCC-FE0D1B54D291Q28079168-D7E1BF49-DCB0-4B88-A2FF-C3605D966C21Q28087621-54A13ADF-074D-44B2-92DF-154E8DA9BABBQ28285877-8D866E06-441E-432A-8779-5845D9300674Q30238812-D3BED0E4-D10F-4384-8C01-6FA59587248EQ30491777-862DBF45-CEAB-41E2-ACE2-7D100E544680Q30614811-9A5BC119-C688-4787-A35E-CB2EBEA0A2C2Q33687552-C191C2DE-FAEB-4370-AB79-F583A7E5FDC3Q33786013-91373FDE-9FA7-41CF-B1CC-CB02FEF219B9Q33798345-2A595C51-EE31-414C-A7F0-007DFFE86EECQ33984216-9122EABD-3979-41AF-8582-9EE8C89A60C1Q34099766-6141D15D-CA54-4530-9411-E92F5F51B411Q34353787-672EBB6E-3183-4CA4-8F6E-B71777B59499Q34639656-CD86629F-2B0C-434B-9659-B14C1632DCF7Q34645986-8531DC45-9D00-4D8D-9315-DB816D8D192BQ34726696-8EF3DC46-45AC-4C15-93AF-E19BE811CF85Q34846428-7BD2022F-4E35-468E-BE98-70AD10B54B63Q35553851-77DEA84C-B907-4CD3-A20E-65718C4BBB19Q35557435-41C1E268-A1E0-4BF7-BD64-B08C9BC8492AQ36192077-FACF1D8A-7DF9-4622-92AE-132A5EADC67FQ36322918-C518B153-3298-40E6-AAF2-42A4B19F71A0Q36482888-4791556F-C57D-4FBC-8A50-0D28632F7011Q36634909-80697AA5-0856-42AE-8D04-3D037E691AE3Q36634986-B28F6292-34A0-4B1D-8FBC-AF0F198C14FAQ36733922-C76BC56A-0EF8-4B15-8737-8F9E7A8554BCQ37030741-A9DC8422-590F-474F-9F60-E31ACC7E74CBQ37042128-F73662CE-DC18-496F-86A7-1765893818BCQ37321757-4EC21D41-9DE5-4A51-B069-43F020ABE60EQ37336958-E57A0926-FD22-4441-84C3-170824C60225Q37367679-01F78EF1-A08E-46FF-9F23-E0A9945CB8F9Q37375516-854D1A67-7BE4-4EF1-90BF-91E7CD28A305Q37391009-7EDB1E83-F03D-4F11-82CC-F3EDB1456F27Q37461431-EFA429FE-8B4D-4F7F-A32B-D13D2BA4AE52Q37474175-8C2CC1DB-257B-4368-A0C5-5B5D4A759B8FQ37575644-CB2EF9D9-64DB-4291-B4F4-B12D137134B8Q37622756-DC6D41CF-8B9E-4B43-8A47-2FF4F735C6F3Q37628518-0316C41D-CBB1-4EEC-AA8B-E7027CC45C3CQ37645239-21BACC81-F472-4579-A909-725AE7D6CBC7Q37650711-7D2C900B-3CCD-4A11-9BCA-1B9512D02AA3Q37728538-72C25F59-07FB-4BEC-8ACE-50822183F02E
P2860
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@en
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@nl
type
label
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@en
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@nl
prefLabel
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@en
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@nl
P2093
P2860
P356
P1476
Emerging evidence of the impact of kidney disease on drug metabolism and transport.
@en
P2093
P2860
P304
P356
10.1038/CLPT.2008.59
P407
P577
2008-04-02T00:00:00Z